The oral vaccine based on self-replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants alpha and delta.
Administration, Oral
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
COVID-19
/ blood
COVID-19 Vaccines
/ administration & dosage
Caco-2 Cells
Cytokines
/ blood
HEK293 Cells
Humans
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Liposomes
/ administration & dosage
Mice, Inbred BALB C
Nanoparticles
/ administration & dosage
Neutralization Tests
RNA
/ administration & dosage
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ genetics
B.1.1.7 lineage
B.1.617 lineage
Oral vaccine
Self-replicating RNA
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
27
07
2021
revised:
22
09
2021
accepted:
04
10
2021
pubmed:
17
10
2021
medline:
21
12
2021
entrez:
16
10
2021
Statut:
ppublish
Résumé
The aim of this study was to evaluate self-replicating RNA lipid nanoparticles (saRNA LNPs) to neutralize SARS-CoV-2 variants delta (B.1.617 lineage) and alpha (B.1.1.7 lineage). Before immunization of mice with saRNA LNPs, we saw high expression of S-protein at both mRNA and protein levels after transfection of HEK293T/17 cells with saRNA LNPs. After oral immunization of BALB/c mice with 0.1 - 10 µg saRNA LNPs , a high quantity of SARS-CoV-2 specific IgG and IgA antibodies were seen with a dose-dependent pattern. Importantly, the ratio of IgG2a/IgG1 in serum of vaccinated mice showed Th1/Th2 skewing response. We also found that the secreted antibodies could neutralize SARS-CoV-2 variants delta (B.1.617 lineage) and alpha (B.1.1.7 lineage). Re-stimulated splenocytes of vaccinated mice showed high secretion of IFN-γ, IL-6, and TNF- α . The authors think that although the preclinical study confirmed the efficacy of saRNA LNPs against SARS-CoV-2, the actual efficacy and safety of the oral vaccine must be evaluated in clinical trials.
Identifiants
pubmed: 34655852
pii: S1567-5769(21)00867-5
doi: 10.1016/j.intimp.2021.108231
pmc: PMC8495003
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Cytokines
0
Immunoglobulin A
0
Immunoglobulin G
0
Lipid Nanoparticles
0
Liposomes
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108231Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
J Microbiol. 2021 Mar;59(3):332-340
pubmed: 33624270
Mol Ther. 2018 Feb 7;26(2):446-455
pubmed: 29275847
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445702
Gastroenterology. 2003 Oct;125(4):1011-7
pubmed: 14517783
Signal Transduct Target Ther. 2021 May 22;6(1):203
pubmed: 34023862
Emerg Microbes Infect. 2013 Aug;2(8):e52
pubmed: 26038486
Drug Deliv Transl Res. 2021 Apr;11(2):353-372
pubmed: 33598818
Subcell Biochem. 2018;88:39-71
pubmed: 29900492
ACS Infect Dis. 2019 Sep 13;5(9):1546-1558
pubmed: 31290323
Adv Drug Deliv Rev. 2021 Mar;170:83-112
pubmed: 33400957
Medchemcomm. 2017 Oct 17;9(2):226-238
pubmed: 30108916
Mucosal Immunol. 2021 May;14(3):566-573
pubmed: 33608656
Gene Ther. 2019 Sep;26(9):363-372
pubmed: 31300730
N Engl J Med. 2020 Jun 18;382(25):2469-2471
pubmed: 32558474
Cell Mol Life Sci. 2019 Jan;76(2):301-328
pubmed: 30334070
Sci Adv. 2020 Aug 07;6(32):eaba5068
pubmed: 32821824
Lancet Infect Dis. 2021 Aug;21(8):1097-1106
pubmed: 33811817
ACS Nano. 2020 May 26;14(5):5711-5727
pubmed: 32267667
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
J Pharm Pract. 2022 Dec;35(6):947-951
pubmed: 33840294
Immunol Rev. 2004 Jun;199:251-63
pubmed: 15233739
Nat Commun. 2020 Jul 9;11(1):3523
pubmed: 32647131
Vaccines (Basel). 2021 Jan 28;9(2):
pubmed: 33525396
Mol Ther Nucleic Acids. 2019 Sep 6;17:767-775
pubmed: 31446119
NPJ Vaccines. 2020 Feb 4;5:11
pubmed: 32047656
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
ACS Cent Sci. 2021 Apr 28;7(4):512-533
pubmed: 34056083
Nat Commun. 2021 May 17;12(1):2893
pubmed: 34001897